Dr Reddy’s string of announcements fails to impress analysts; stock could fall 30%

Kotak Securities has a ‘sell’ recommendation on the stock with the target at Rs 3,700, a potential downside of over 30 per cent from current market price as it believes risk-reward of the scrip is unfavourable.